Key Points
-
Elevated blood pressure can occur as a result of, and be a potent risk factor for, chronic kidney disease (CKD) progression
-
CKD is associated with dysregulation of various blood pressure control systems, including the ability to excrete the daily sodium load, sympathetic activation, renin–angiotensin system activity, and endothelial function
-
Although controversial, the Joint National Committee recommends target blood pressure levels <140/90 mmHg in US patients with CKD until 70 years of age
-
Most guidelines for hypertension treatment in CKD recommend administration of an agent that blocks the renin–angiotensin system, with follow-up testing of kidney function and serum potassium concentrations
-
Home and ambulatory blood pressure monitoring can improve the assessment of overall blood pressure control in patients with CKD, as compared to office measurements alone
-
Device-based methods for blood pressure reduction, such as renal denervation and baroreceptor activation therapy, suggest safety in CKD; unequivocal efficacy remains to be shown in sham-controlled studies
Abstract
Hypertension is a common comorbidity in patients with impaired kidney function. The kidney exerts a marked degree of control over blood pressure through various mechanisms, such as by regulating sodium balance and hormone secretion through the activity of the renin–angiotensin system. The kidney is susceptible to injury, and if already damaged can be at risk of further loss of function as a consequence of elevated blood pressure. Once elevated blood pressure is identified, a combination of sensible lifestyle measures, such as sodium restriction and weight loss, with pharmacological intervention to reduce blood pressure will usually achieve blood pressure goals. In this Review, we outline the importance of blood pressure control for patients with chronic kidney disease (CKD), the mechanisms that affect blood pressure control, and the basis for non-drug and drug therapies. We further discuss the rationale for <140 mmHg systolic and <90 mmHg diastolic targets for blood pressure in patients with CKD, with consideration for tighter targets in the setting of proteinuria.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stevens, P. E. & Levin, A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825–830 (2013).
Muntner, P. et al. Hypertension awareness, treatment, and control in adults with chronic kidney disease: results from the Chronic Renal Insufficiency Cohort (CRIC) study. Am. J. Kidney Dis. 55, 441–451 (2009).
Bakris, G. L. et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 36, 646–661 (2000).
Young, J. H. et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Soc. Nephrol. 13, 2776–2782 (2002).
Palmer, B. F. Hypertension management in patients with chronic kidney disease. Curr. Hypertens. Rep. 10, 367–373 (2008).
Rao, M. V., Qiu, Y., Wang, C. & Bakris, G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999–2004. Am. J. Kidney Dis. 51 (Suppl. 2), S30–S37 (2008).
Matsushita K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081 (2010).
Ren, Y. et al. Mechanism of impaired afferent arteriole myogenic response in Dahl salt-sensitive rats: role of 20-HETE. Am. J. Physiol. Renal Physiol. 307, F533–F538 (2014).
Rhaleb, N. E., Yang, X. P. & Carretero, O. A. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr. Physiol. 1, 971–993 (2011).
Elijovich, F. 20-HETE and salt-sensitivity of blood pressure a novel emerging concept. Am. J. Hypertens. 19, 1181–1182 (2006).
Sharma, J. N. & Narayanan, P. The kallikrein-kinin pathways in hypertension and diabetes. Prog. Drug Res. 69, 15–36 (2014).
Ito, Y. et al. Norepinephrine responsiveness in patients with borderline hypertension under three different sodium balances. Clin. Exp. Hypertens. A. 11 (Suppl 1), 363–370 (1989).
Hovater, M. B. & Sanders, P. W. Effect of dietary salt on regulation of TGF-beta in the kidney. Semin. Nephrol. 32, 269–276 (2012).
Koomans, H. A., Roos, J. C., Boer, P., Geyskes, G. G. & Mees, E. J. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 4, 190–197 (1982).
Esler, M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J. Appl. Physiol. 108, 227–237 (2010).
Converse, R. L. et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 327, 1912–1918 (1992).
Klein, I. H., Ligtenberg, G., Neumann, J., Oey, P. L., Koomans, H. A. & Blankestijn, P. J. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J. Am. Soc. Nephrol. 14, 3239–3244 (2003).
DiBona, G. F. & Kopp, U. C. Neural control of renal function. Physiol. Rev. 77, 75–197 (1997).
Kobori, H., Nangaku, M., Navar, L. G. & Nishiyama, A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251–287 (2007).
Conn, J. W. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 45, 3–17 (1955).
Greene, E. L., Kren, S. & Hostetter, T. H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063–1068 (1996).
Deo, R. et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 64, 103–110 (2014).
Briet, M. & Schiffrin, E. L. Vascular actions of aldosterone. J. Vasc. Res. 50, 89–99 (2013).
Richter, C. M. Role of endothelin in chronic renal failure—developments in renal involvement. Rheumatology (Oxford) 45 (Suppl 3), iii36–iii38 (2006).
Araujo, M. & Wilcox, C. S. Oxidative stress in hypertension: role of the kidney. Antioxid. Redox Signal. 20, 74–101 (2014).
Crowley, S. D. The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antioxid. Redox Signal. 20, 102–120 (2014).
Lee, J. Nitric oxide in the kidney: its physiological role and pathophysiological implications. Electrolyte Blood Press 6, 27–34 (2008).
LeLorier, J. et al. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can. J. Cardiol. 18, 1301–1308 (2002).
Verdecchia, P. et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24, 793–801 (1994).
Shimada, K., Kawamoto, A., Matsubayashi, K. & Ozawa, T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 16, 692–699 (1990).
Verdecchia, P., Angeli, F. & Cavallini, C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation 115, 2091–2093 (2007).
Kario, K. et al. Sleep pulse pressure and awake mean pressure as independent predictors for stroke in older hypertensive patients. Am. J. Hypertens. 17, 439–445 (2004).
Cohen, D. L., Huan, Y. & Townsend, R. R. Home blood pressure monitoring in CKD. Am. J. Kidney Dis. 63, 835–842 (2014).
Minutolo, R. et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch. Intern. Med. 171, 1090–1098 (2011).
Agarwal, R. & Andersen, M. J. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am. J. Nephrol. 26, 503–510 (2006).
Myers, M. G., Godwin, M., Dawes, M., Kiss, A., Tobe, S. W. & Kaczorowski, J. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 55, 195–200 (2010).
Stergiou, G. S., Parati, G., Asmar, R. & O'Brien, E. Requirements for professional office blood pressure monitors. J. Hypertens. 30, 537–542 (2012).
Graves, J. W., Nash, C., Burger, K., Bailey, K. & Sheps, S. G. Clinical decision-making in hypertension using an automated (BpTRU) measurement device. J. Hum. Hypertens. 17, 823–827 (2003).
Myers, M. G., Valdivieso, M., Kiss, A. & Tobe, S. W. Comparison of two automated sphygmomanometers for use in the office setting. Blood Press. Monit. 14, 45–47 (2009).
Myers, M. G. & Godwin, M. Automated office blood pressure. Can. J. Cardiol. 28, 341–346 (2012).
Wolk, R., Shamsuzzaman, A. S. & Somers, V. K. Obesity, sleep apnea, and hypertension. Hypertension 42, 1067–1074 (2003).
Dolan, E. et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46, 156–161 (2005).
Pogue, V. et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 53, 20–27 (2009).
Kanno, A. et al. Night-time blood pressure is associated with the development of chronic kidney disease in a general population: the Ohasama Study. J. Hypertens. 31, 2410–2417 (2013).
Kimura, G. Kidney and circadian blood pressure rhythm. Hypertension 51, 827–828 (2008).
Brunelli, S. M. et al. Association between long-term blood pressure variability and mortality among incident hemodialysis patients. Am. J. Kidney Dis. 52, 716–726 (2008).
Ciobanu, A. O. et al. The impact of blood pressure variability on subclinical ventricular, renal and vascular dysfunction, in patients with hypertension and diabetes. Maedica (Buchar.) 8, 129–136 (2013).
Muntner, P. et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 57, 160–166 (2011).
Mancia, G. Prognostic value of long-term blood pressure variability: the evidence is growing. Hypertension 57, 141–143 (2011).
Parati, G. & Valentini, M. Prognostic relevance of blood pressure variability. Hypertension 47, 137–138 (2006).
Rave, K., Bender, R., Heise, T. & Sawicki, P. T. Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy. J. Hypertens. 17, 597–601 (1999).
Agarwal, R. & Andersen, M. J. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am. J. Nephrol. 26, 503–510 (2006).
Pickering, T. G. et al. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 52, 1–9 (2008).
Alborzi, P., Patel, N. & Agarwal, R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin. J. Am. Soc. Nephrol. 2, 1228–1234 (2007).
Agarwal, R. et al. Assessment and management of hypertension in patients on dialysis. J. Am. Soc. Nephrol. 25, 1630–1646 (2014).
Cappuccio, F. P., Kerry, S. M., Forbes, L. & Donald, A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ 329, 145 (2004).
Lash, J. P. et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin. J. Am. Soc. Nephrol. 4, 1302–1311 (2009).
Shulman, N. B. et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13, I80–I93 (1989).
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
McCullough, P. A. et al. Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). Curr. Diab. Rep. 11, 47–55 (2011).
Whaley-Connell, A., Nistala, R. & Chaudhary, K. The importance of early identification of chronic kidney disease. Mo. Med. 108, 25–28 (2011).
Whaley-Connell, A. T. et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am. J. Kidney Dis. 51, S13–S20 (2008).
Loutzenhiser, R., Bidani, A. K. & Wang, X. Systolic pressure and the myogenic response of the renal afferent arteriole. Acta Physiol. Scand. 181, 407–413 (2004).
Bidani, A. K., Polichnowski, A. J., Loutzenhiser, R. & Griffin, K. A. Renal microvascular dysfunction, hypertension and CKD progression. Curr. Opin. Nephrol. Hypertens. 22, 1–9 (2013).
Anderson, S. & Brenner, B. M. Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. Am. J. Hypertens. 1, 380S–383S (1988).
Anderson, S., Brenner, B. M. Progressive renal disease: a disorder of adaptation. Q. J. Med. 70, 185–189 (1989).
Klahr, S. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N. Engl. J. Med. 330, 877–884 (1994).
Wright, J. T. Jr et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288, 2421–2431 (2002).
Ruggenenti, P. et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365, 939–946 (2005).
Upadhyay, A., Earley, A., Haynes, S. M. & Uhlig, K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann. Intern. Med. 154, 541–548 (2011).
Jafar, T. H. et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 139, 244–252 (2003).
Kovesdy, C. P. et al. Blood pressure and mortality in US veterans with chronic kidney disease: a cohort study. Ann. Intern. Med. 159, 233–242 (2013).
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358, 1033–1041 (2001).
Cushman, W. C. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
Kovesdy, C. P. et al. Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern. Med. 174, 1442–1449 (2014).
KDIGO Panel. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. Suppl. 2, 343–387 (2012).
American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 36 (Suppl 1), S11–S66 (2013).
Daskalopoulou, S. S., Rabi, D.M., Zarnke, K.B. & Dasgupta, K. et al. for the Canadian Hypertension Education Program. The 2015 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can. J. Cardiol. 31, 549–568 (2015).
Mancia, G. et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281–1357 (2013).
National Institute for Care Excellence. Hypertension: Clinical management of primary hypertension in adults [online], (2011).
Carville, S., Wonderling, D. & Stevens, P. Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. BMJ 349, g4507 (2014).
Sakhuja, A., Textor, S. C. & Taler, S. J. Uncontrolled hypertension by the evidence-based guideline: results from NHANES 2011–2012. J. Hypertens. 644–651 (2015).
Ajani, U. A. et al. Sodium intake among people with normal and high blood pressure. Am. J. Prev. Med. 29 (Suppl. 1), 63–67 (2005).
Laragh, J. H. et al. The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. Am. J. Med. 58, 4–13 (1975).
Davis, J. O. & Freeman, R. H. Mechanisms regulating renin release. Physiol. Rev. 56, 1–56 (1976).
Mehta, P. K. & Griendling, K. K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82–C97 (2007).
McEniery, C. M. et al. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. Hypertension 53, 524–531 (2009).
Townsend, R. R. & Tomiyama, H. Arterial stiffness, kidney function and chronic kidney disease progression. Pulse 1, 123–130 (2013).
Mimran, A. & Du, C. G. Dietary sodium: the dark horse amongst cardiovascular and renal risk factors. Nephrol. Dial. Transplant. 23, 2138–2141 (2008).
Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D. & Navis, G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19, 999–1007 (2008).
James, P. A. et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA 311, 507–520 (2014).
Holtkamp, F. A. et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 80, 282–287 (2011).
Hricik, D. E. et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N. Engl. J. Med. 308, 373–376 (1983).
Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547–1559 (2008).
Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892–1903 (2013).
Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).
Pfeffer, M. A. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759–766 (2003).
Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383–1392 (2014).
Krum, H. et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS–HF study. Circ. Heart Fail. 6, 711–718 (2013).
Bomback, A. S. et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am. J. Kidney Dis. 51, 199–211 (2008).
Sica, D. A. The kidney and hypertension: causes and treatment. J. Clin. Hypertens. (Greenwich) 10, 541–548 (2008).
Ecder, T. et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am. J. Nephrol. 21, 98–103 (2001).
Torres, V. E. et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2267–2276 (2014).
Uzu, T. & Kimura, G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 100, 1635–1638 (1999).
Bakris, G. L. et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 65, 1991–2002 (2004).
Ruggenenti, P., Perna, A., Benini, R. & Remuzzi, G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. 9, 2096–2101 (1998).
Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375, 1173–1181 (2010).
Weir, M. R. et al. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 81, 568–576 (2012).
Prichard, B. N., Cruickshank, J. M. & Graham, B. R. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press. 10, 366–386 (2001).
Taler, S. J., Textor, S. C. & Augustine, J. E. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 39, 982–988 (2002).
Karadsheh, F. & Weir, M. R. Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease. Curr. Hypertens. Rep. 14, 416–420 (2012).
Hou, F. F. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 354, 131–140 (2006).
Yasuda, T. et al. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT). Hypertens. Res. 36, 240–246 (2013).
Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275–1281 (2009).
Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).
Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393–1401 (2014).
Hering, D. et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23, 1250–1257 (2012).
Gassler, J. P. & Bisognano, J. D. Baroreflex activation therapy in hypertension. J. Hum. Hypertens. 28, 469–474 (2014).
Heusser, K. et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55, 619–626 (2010).
Scheffers, I. J. et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J. Am. Coll. Cardiol. 56, 1254–1258 (2010).
Bisognano, J. D. et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J. Am. Coll. Cardiol. 58, 765–773 (2011).
Wallbach, M. et al. Impact of baroreflex activation therapy on renal function—a pilot study. Am. J. Nephrol. 40, 371–380 (2014).
Weber, M. A. et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J. Hypertens. 32, 3–15 (2014).
Flack, J. M. et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 56, 780–800 (2010).
National Institute for Care Excellence. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care [online], (2014).
Author information
Authors and Affiliations
Contributions
Both authors researched data for the article, provided substantial contributions to discussion of its content, wrote the article and undertook review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Townsend, R., Taler, S. Management of hypertension in chronic kidney disease. Nat Rev Nephrol 11, 555–563 (2015). https://doi.org/10.1038/nrneph.2015.114
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.114
This article is cited by
-
Tamoxifen associated to the conservative CKD treatment promoted additional antifibrotic effects on experimental hypertensive nephrosclerosis
Scientific Reports (2023)
-
Epigallocatechin gallate protects against homocysteine-induced vascular smooth muscle cell proliferation
Molecular and Cellular Biochemistry (2018)
-
Gender differences in hypertension awareness, antihypertensive use and blood pressure control in Bangladeshi adults: findings from a national cross-sectional survey
Journal of Health, Population and Nutrition (2017)
-
Chronotherapy for hypertension in patients with chronic kidney disease: a systematic review and meta-analysis in non-black patients
International Urology and Nephrology (2017)
-
Management of Hypertension in Patients with Chronic Kidney Disease
Current Hypertension Reports (2017)